{
  "guid": "urn:uuid:1c35c1d9-5590-4639-8d9a-455a68ca71ba",
  "link": "https://www.who.int/news/item/02-04-2022-suspension-of-supply-of-covid-19-vaccine-covaxin",
  "a10:author": {
    "a10:name": ""
  },
  "title": "Suspension of supply of COVID-19 vaccine (COVAXIN®)",
  "description": "Suspension of supply of Covaxin produced by Bharat, through UN procurement agencies and recommending to countries that received the vaccine to take actions as appropriate.",
  "pubDate": "Mon, 04 Apr 2022 09:59:26 Z",
  "a10:content": "<p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\">Today, WHO confirmed the suspension of supply of Covaxin (Bharat Biotech) through UN procurement agencies, and recommended that countries using the vaccine take action as appropriate.</span></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\">The suspension is in response to the outcome of a WHO inspection on 14 &ndash; 22 March 2022, and the need to conduct process and facility upgrade to address recently identified deficiencies in good manufacturing practices (GMP).</span><br /></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\">Bharat Biotech has committed to addressing the GMP deficiencies and is developing a corrective and preventive action plan for submission to the Drugs Controller General of India (DCGI) and WHO. In the interim and as a precautionary measure, the company has indicated that it will suspend production of Covaxin for export. As a consequence, supply will be interrupted for the foreseeable future.</span><br /></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\">The risk assessment to date does not indicate change in the risk-benefit ratio. The data, available to WHO, indicate the vaccine is effective and no safety concerns exist.</span><br /></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\">For continuation of vaccination with alternative sources of Covid 19 vaccines, countries should refer to the respective SAGE recommendation:&nbsp;</span><a href=\"https://www.who.int/publications/m/item/considerations-for-the-assessment-of-covid-19-vaccines-for-listing-by-who\" style=\"font-size:inherit;font-family:inherit;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;\" target=\"_blank\">Considerations for the Assessment of COVID-19 Vaccines for Listing by WHO</a><span style=\"background-color:initial;color:#333333;font-size:inherit;font-family:inherit;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\"></span></p>"
}